U.S. Markets closed
  • S&P 500

    3,825.33
    +39.95 (+1.06%)
     
  • Dow 30

    31,097.26
    +321.83 (+1.05%)
     
  • Nasdaq

    11,127.84
    +99.11 (+0.90%)
     
  • Russell 2000

    1,727.76
    +19.77 (+1.16%)
     
  • Crude Oil

    108.46
    +2.70 (+2.55%)
     
  • Gold

    1,812.90
    +5.60 (+0.31%)
     
  • Silver

    19.85
    -0.50 (-2.44%)
     
  • EUR/USD

    1.0426
    -0.0057 (-0.5422%)
     
  • 10-Yr Bond

    2.8890
    -0.0830 (-2.79%)
     
  • Vix

    26.70
    -2.01 (-7.00%)
     
  • GBP/USD

    1.2103
    -0.0072 (-0.5930%)
     
  • USD/JPY

    135.1750
    -0.5530 (-0.4074%)
     
  • BTC-USD

    19,022.90
    -105.69 (-0.55%)
     
  • CMC Crypto 200

    420.84
    +0.70 (+0.17%)
     
  • FTSE 100

    7,168.65
    -0.63 (-0.01%)
     
  • Nikkei 225

    25,935.62
    -457.42 (-1.73%)
     

Quest Diagnostics Reports Third Quarter 2021 Financial Results, Raises Outlook for Full Year 2021

  • Oops!
    Something went wrong.
    Please try again later.
·12 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

- Third quarter revenues of $2.77 billion, down 0.4% from 2020

- Third quarter reported diluted earnings per share ("EPS") of $4.02, down 2.8% from 2020; and adjusted diluted EPS of $3.96, down 7.9% from 2020

- Year to date cash provided by operations of $1.75 billion, up 19.6% from 2020

- Raises full year 2021 outlook to reflect higher than anticipated COVID-19 testing volumes and base business performance

SECAUCUS, N.J., Oct. 21, 2021 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results for the third quarter ended September 30, 2021.

Quest Diagnostics Incorporated logo. (PRNewsFoto/Quest Diagnostics Incorporated)
Quest Diagnostics Incorporated logo. (PRNewsFoto/Quest Diagnostics Incorporated)

"We had a strong third quarter, as COVID-19 molecular volumes increased throughout the summer while our base business continued to deliver solid volume growth versus the prior year and 2019," said Steve Rusckowski, Chairman, CEO and President. "In late summer we experienced some softness in the base business across the country, but saw an overall rebound in September. Importantly, our base business continued to improve sequentially in the third quarter which speaks to the ongoing recovery."

"We have raised our outlook for the remainder of the year based on higher than anticipated COVID-19 volumes as well as the continued progress we expect to see in our base business despite rising labor costs and inflationary pressures. The momentum of our base business positions us to deliver the 2022 outlook we shared at our March investor day."


Three Months Ended September 30,


Nine Months Ended September 30,



2021


2020


Change


2021


2020


Change



(dollars in millions, except per share data)


Reported:













Net revenues

$

2,774



$

2,786



(0.4)

%


$

8,044



$

6,435



25.0

%


Diagnostic Information Services revenues

$

2,703



$

2,709



(0.2)

%


$

7,820



$

6,217



25.8

%


Revenue per requisition





(5.4)

%






2.2

%


Requisition volume





5.3

%






22.9

%


Organic requisition volume





3.2

%






19.2

%


Operating income (a)

$

652



$

718



(9.3)

%


$

1,845



$

1,176



56.9

%


Operating income as a percentage of net revenues (a)

23.5

%


25.8

%


(2.3)

%


22.9

%


18.3

%


4.6

%


Net income attributable to Quest Diagnostics (a)

$

505



$

568



(11.0)

%


$

1,605



$

852



88.4

%


Diluted EPS (a) (b)

$

4.02



$

4.14



(2.8)

%


$

12.41



$

6.25



98.5

%


Cash provided by operations

$

561



$

862



(34.9)

%


$

1,752



$

1,464



19.6

%


Capital expenditures

$

89



$

91



(1.9)

%


$

259



$

256



1.2

%















Adjusted (a):













Operating income

$

694



$

831



(16.4)

%


$

1,986



$

1,350



47.1

%


Operating income as a percentage of net revenues

25.0

%


29.8

%


(4.8)

%


24.7

%


21.0

%


3.7

%


Net income attributable to Quest Diagnostics

$

498



$

591



(15.7)

%


$

1,411



$

912



54.7

%


Diluted EPS (b)

$

3.96



$

4.31



(7.9)

%


$

10.91



$

6.69



63.1

%




(a)

For further details impacting the year-over-year comparisons related to operating income, operating income as a percentage of net
revenues, net income attributable to Quest Diagnostics, and diluted EPS, see note 2 of the financial tables attached below.



(b)

The sum of reported and adjusted diluted EPS for the first three quarters of 2021 did not equal the totals for the nine months ended September 30, 2021 due to both quarterly fluctuations in the company's earnings and in the weighted average common shares outstanding throughout the period as a result of the impact of accelerated share repurchase agreements ("ASRs") that the company entered into during April 2021.

Updated Outlook for Full Year 2021

The company updates its Full Year 2021 outlook as follows:


Updated Outlook


Previous Outlook


Low


High


Low


High

Net revenues

$10.45 billion


$10.60 billion


$9.84 billion


$10.09 billion

Net revenues increase

10.7%


12.3%


4.3%


6.9%

Reported diluted EPS

$14.69


$15.09


$12.54


$13.24

Adjusted diluted EPS

$13.50


$13.90


$11.65


$12.35

Cash provided by operations

Approximately $2.2 billion


At least $2.0 billion

Capital expenditures

Approximately $400 million


Approximately $400 million

Note on Non-GAAP Financial Measures

As used in this press release the term "reported" refers to measures under accounting principles generally accepted in the United States ("GAAP"). The term "adjusted" refers to non-GAAP operating performance measures that exclude special items such as restructuring and integration charges, certain financial impacts resulting from the COVID-19 pandemic, amortization expense, excess tax benefits ("ETB") associated with stock-based compensation, costs associated with donations, contributions, and other financial support through Quest for Health Equity, the company's initiative with the Quest Diagnostics Foundation to reduce health disparities in underserved communities, a gain on sale of an ownership interest in a joint venture, gains associated with changes in the carrying value of our strategic investments, and other items.

Non-GAAP adjusted measures are presented because management believes those measures are useful adjuncts to GAAP results. Non-GAAP adjusted measures should not be considered as an alternative to the corresponding measures determined under GAAP. Management may use these non-GAAP measures to evaluate our performance period over period and relative to competitors, to analyze the underlying trends in our business, to establish operational budgets and forecasts and for incentive compensation purposes. We believe that these non-GAAP measures are useful to investors and analysts to evaluate our performance period over period and relative to competitors, as well as to analyze the underlying trends in our business and to assess our performance. The additional tables attached below include reconciliations of non-GAAP adjusted measures to GAAP measures.

Conference Call Information

Quest Diagnostics will hold its quarterly conference call to discuss financial results beginning at 8:30 a.m. Eastern Time today. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, passcode: 7895081; or via live webcast on the company's website at www.QuestDiagnostics.com/investor. The company suggests participants dial in approximately 10 minutes before the call.

A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or, from approximately 10:30 a.m. Eastern Time on October 21, 2021 until midnight Eastern Time on November 4, 2021, by phone at 866-360-7722 for domestic callers or 203-369-0174 for international callers. Anyone listening to the call is encouraged to read the company's periodic reports, on file with the Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.

About Quest Diagnostics

Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our nearly 50,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com.

Forward Looking Statements

The statements in this press release which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, impacts of the COVID-19 pandemic and measures taken in response, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, the complexity of billing, reimbursement and revenue recognition for clinical laboratory testing, changes in government regulations, changing relationships with customers, payers, suppliers or strategic partners and other factors discussed in the company's most recently filed Annual Report on Form 10-K and in any of the company's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the "Business," "Risk Factors," "Cautionary Factors that May Affect Future Results" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of those reports.

This earnings release, including the attached financial tables, is available online in the Newsroom section at www.QuestDiagnostics.com.

ADDITIONAL TABLES FOLLOW



Quest Diagnostics Incorporated and Subsidiaries

Consolidated Statements of Operations

For the Three and Nine Months Ended September 30, 2021 and 2020

(in millions, except per share data)

(unaudited)



Three Months Ended
September 30,


Nine Months Ended
September 30,


2021


2020


2021


2020

Net revenues

$

2,774



$

2,786



$

8,044



$

6,435










Operating costs and expenses and other operating income:








Cost of services

1,670



1,580



4,861



4,071


Selling, general and administrative

427



396



1,263



1,103


Amortization of intangible assets

25



27



77



77


Other operating expense (income), net



65



(2)



8


Total operating costs and expenses, net

2,122



2,068



6,199



5,259










Operating income

652



718



1,845



1,176










Other income (expense):








Interest expense, net

(38)



(42)



(114)



(124)


Other income, net

40



77



366



74


Total non-operating income (expense), net

2



35



252



(50)










Income before income taxes and equity in earnings of equity method
investees

654



753



2,097



1,126


Income tax expense

(153)



(177)



(483)



(269)


Equity in earnings of equity method investees, net of taxes

26



15



53



33


Net income

527



591



1,667



890


Less: Net income attributable to noncontrolling interests

22



23



62



38


Net income attributable to Quest Diagnostics

$

505



$

568



$

1,605



$

852










Earnings per share attributable to Quest Diagnostics' common
stockholders:








Basic

$

4.11



$

4.20



$

12.63



$

6.33










Diluted

$

4.02



$

4.14



$

12.41



$

6.25










Weighted average common shares outstanding:








Basic

123



135



127



134










Diluted

125



137



129



136


Quest Diagnostics Incorporated and Subsidiaries

Consolidated Balance Sheets

September 30, 2021 and December 31, 2020

(in millions, except per share data)

(unaudited)



September 30,
2021


December 31,
2020

Assets




Current assets:




Cash and cash equivalents

$

987



$

1,158


Accounts receivable, net

1,473



1,520


Inventories

205



223


Prepaid expenses and other current assets

189



157


Total current assets

2,854



3,058


Property, plant and equipment, net

1,634



1,627


Operating lease right-of-use assets

596



604


Goodwill

7,057



6,873


Intangible assets, net

1,152



1,167


Investments in equity method investees

124



521


Other assets

155



176


Total assets

$

13,572



$

14,026






Liabilities and Stockholders' Equity




Current liabilities:




Accounts payable and accrued expenses

$

1,610



$

1,633


Current portion of long-term debt

1



2


Current portion of long-term operating lease liabilities

148



141


Total current liabilities

1,759



1,776


Long-term debt

4,006



4,013


Long-term operating lease liabilities

495



499


Other liabilities

801



847


Redeemable noncontrolling interest

79



82


Stockholders' equity:




Quest Diagnostics stockholders' equity:




Common stock, par value $0.01 per share; 600 shares authorized as of both September 30, 2021 and December 31, 2020; 162 and 217 shares issued as of September 30, 2021 and December 31, 2020, respectively

2



2


Additional paid-in capital

1,936



2,841


Retained earnings

7,333



9,303


Accumulated other comprehensive loss

(13)



(21)


Treasury stock, at cost; 39 and 84 shares as of September 30, 2021 and December 31, 2020, respectively

(2,866)



(5,366)


Total Quest Diagnostics stockholders' equity

6,392



6,759


Noncontrolling interests

40



50


Total stockholders' equity

6,432



6,809


Total liabilities and stockholders' equity

$

13,572



$

14,026


Quest Diagnostics Incorporated and Subsidiaries

Consolidated Statements of Cash Flows

For the Nine Months Ended September 30, 2021 and 2020

(in millions)

(unaudited)



Nine Months Ended
September 30,


2021


2020

Cash flows from operating activities:




Net income

$

1,667



$

890


Adjustments to reconcile net income to net cash provided by operating activities:




Depreciation and amortization

302



263


Provision for credit losses

3



18


Deferred income tax (benefit) provision

(87)



12


Stock-based compensation expense

60



63


Gain on disposition of joint venture

(314)




Other, net

(48)



(60)


Changes in operating assets and liabilities:




Accounts receivable

45



(355)


Accounts payable and accrued expenses

36



514


Income taxes payable

49



95


Termination of interest rate swap agreements



40


Other assets and liabilities, net

39



(16)


Net cash provided by operating activities

1,752



1,464






Cash flows from investing activities:




Business acquisitions, net of cash acquired

(251)



(329)


Capital expenditures

(259)



(256)


Proceeds from disposition of joint venture

755




Decrease (Increase) in investments and other assets

3



(19)


Net cash provided by (used in) investing activities

248



(604)






Cash flows from financing activities:




Proceeds from borrowings



749


Repayments of debt

(2)



(1,002)


Purchases of treasury stock

(1,910)



(75)


Exercise of stock options

108



144


Employee payroll tax withholdings on stock issued under stock-based compensation plans

(22)



(13)


Dividends paid

(232)



(222)


Distributions to noncontrolling interest partners

(75)



(34)


Other financing activities, net

(38)



6


Net cash used in financing activities

(2,171)



(447)






Net change in cash and cash equivalents and restricted cash

(171)



413


Cash and cash equivalents and restricted cash, beginning of period

1,158



1,192


Cash and cash equivalents and restricted cash, end of period

$

987



$

1,605






Cash paid during the period for:




Interest

$

111



$

136


Income taxes

$

522



$

168


...

Notes to Financial Tables


1) The computation of basic and diluted earnings per common share is as follows:



Three Months Ended
September 30,


Nine Months Ended
September 30,


2021


2020


2021


2020


(in millions, except per share data)

Amounts attributable to Quest Diagnostics' common stockholders:








Net income attributable to Quest Diagnostics

...